TScan Therapeutics announced an accepted abstract for poster presentation at ASGCT's annual meeting on TCR-engineered therapies for cancer. TScan Therapeutics, Inc., a clinical-stage biotechnology ...

Additionally, two abstracts on another drug, AFM24, in combination with atezolizumab for treating non-small cell lung cancer (NSCLC) have been accepted for poster presentations. The oral ...